
Join to View Full Profile
1365 Clifton Rd NeAtlanta, GA 30322
Phone+1 404-778-1900
Dr. Saba is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of TorontoFellowship, Stem cell transplantation , 1998 - 1999
- Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 1994 - 1997
- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1994
- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1990 - 1992
- American University of Beirut Faculty of MedicineClass of 1990
Certifications & Licensure
- GA State Medical License 2003 - 2025
- MA State Medical License 1993 - 2004
- MN State Medical License 1999 - 2004
- RI State Medical License 1995 - 1996
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Atlanta Magazine: Top Doctors Castle Connolly, 2005, 2016
- Distinguished Doctor Expert Network, 2015
- Top Doctor Castle Connolly, 2011, 2014
- Join now to see all
Clinical Trials
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
- Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy Start of enrollment: 2008 Oct 01
- Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Start of enrollment: 2009 Mar 16
- Join now to see all
Publications & Presentations
PubMed
- STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.Nabil F Saba, Kevin Harrington, Lisa Licitra, Jean-Pascal Machiels, Cixin He
Future Oncology. 2025-04-18 - Neoadjuvant chemotherapy and surgery versus surgery for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC) ECOG-ACRIN EA3163.Nabil F Saba, Yael Flamand, Derrick T Lin, Christine H Chung, Mark W McDonald
Clinical Cancer Research. 2025-04-14 - Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline.F Christopher Holsinger, Nofisat Ismaila, Douglas R Adkins, Brittany R Barber, Graham Burnette
Journal of Clinical Oncology. 2025-04-10
Journal Articles
- Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative AnalysisRathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
- Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic CarcinomasJonathan J Beitler, Ryan H Belcher, Richard J Cassidy, Jim Zhong, Conor E Steuer, Nabil F Saba, The Laryngoscope
- Interleukin-6/STAT3 Signaling Is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell CarcinomaNabil F Saba, Dong M Shin, Head and Neck Pathology
- Join now to see all
Lectures
- Nivolumab (nivo) vs investigatoras choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of C...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Posttreatment surveillance of squamous carcinoma of the head and neckSaba NF
http://www.uptodate.com/contents/posttreatment-surveillance-of-squamous-carcinoma-of-the-head-and-ne
UpToDate, Wolters Kluwer Health - 2013-01-22
Press Mentions
- Neoadjuvant Chemo Boosts Structure Preservation Rates in Nasal, Sinus CancerSeptember 19th, 2024
- Head and Neck Cancer Awareness Month: 2022 Immunotherapy Research UpdatesApril 3rd, 2022
- Dr. Nabil F. Saba Answers Questions About Head and Neck Cancer and Immunotherapy After the 2021 CRI Virtual Immunotherapy Patient SummitDecember 10th, 2021
- Join now to see all
Grant Support
- Atorvastatin to Reduce Cisplatin-Induced Hearing Loss in Head and Neck Cancer PatientsEMORY UNIVERSITY2023–2028
- Atorvastatin to Reduce Cisplatin-Induced Hearing Loss in Head and Neck Cancer PatientsEMORY UNIVERSITY2023–2028
- Atorvastatin to Reduce Cisplatin-Induced Hearing Loss in Head and Neck Cancer PatientsEMORY UNIVERSITY2023–2028
- Winship National Clinical Trials Network Lead Academic Participating SiteEMORY UNIVERSITY2019–2025
Committees
- Chair, Chair- NCI steering committee task force on RM HNCA 2017 - Present
- Member, Dean's advisory committee - Emory University School of Medicine 2017 - Present
- Chair, Chair-NCI head and neck cancer steering committee on rare diseases 2016 - Present
- Member, NRG- Head and Neck Cancer Core Committee 2016 - Present
- Principal Author, Member, Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology - Head & Neck Cancer, American College of Radiology 2015 - Present
- Member, Member - head and neck cancer steering committee on metastatic disease 2015 - Present
- Member, ECOG Head and Neck Cancer core committee 2006 - Present
Professional Memberships
- Member
- Fellow
- AHNSMember
Other Languages
- French, Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: